CN114225052A - High-fat meal formula for fat tolerance test - Google Patents
High-fat meal formula for fat tolerance test Download PDFInfo
- Publication number
- CN114225052A CN114225052A CN202111364115.5A CN202111364115A CN114225052A CN 114225052 A CN114225052 A CN 114225052A CN 202111364115 A CN202111364115 A CN 202111364115A CN 114225052 A CN114225052 A CN 114225052A
- Authority
- CN
- China
- Prior art keywords
- fat
- meal
- tolerance test
- fat meal
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 61
- 235000012054 meals Nutrition 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 238000009472 formulation Methods 0.000 claims abstract description 6
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 3
- 239000008103 glucose Substances 0.000 claims abstract description 3
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims abstract description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims abstract description 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims abstract description 3
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 3
- 239000011734 sodium Substances 0.000 claims abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 27
- 239000008280 blood Substances 0.000 abstract description 27
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 230000003068 static effect Effects 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract 1
- 230000000291 postprandial effect Effects 0.000 description 21
- 150000002632 lipids Chemical class 0.000 description 19
- 208000030159 metabolic disease Diseases 0.000 description 16
- 208000031226 Hyperlipidaemia Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000016097 disease of metabolism Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000020925 non fasting Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a high-fat meal formula for a fat tolerance test, and relates to the field of high-fat meal tolerance tests; a high fat meal formulation for a fat tolerance test, as shown in the following table:
Description
Technical Field
The invention relates to the field of high-fat meal tolerance tests, in particular to a high-fat meal formula for a fat tolerance test.
Background
Hyperlipidemia refers to a disease with high blood lipid level, which can directly cause serious harm to human health, such as hypertension, diabetes, atherosclerosis, coronary heart disease, pancreatitis and the like, and is an important risk factor of metabolic diseases. The early intervention and treatment of the hyperlipemia patients can reduce the occurrence and the development of the metabolic diseases. It has been previously thought that plasma total cholesterol concentrations >5.17mmol/L (200mg/dl) can be termed hypercholesterolemia and plasma triacylglycerol concentrations >2.3mmol/L (200mg/dl) are termed hypertriglyceridemia; the established diagnosis standard of postprandial hyperlipemia varies according to different tested people, different testing methods and other factors in various places; the existing hyperlipidemia detection is performed before breakfast, i.e. the testee is required to take a blood sample for detection.
The existing blood lipid inspection is arranged in the morning for fasting blood drawing, but people are in a non-fasting state in most of one day, the fasting state is a special state, the blood lipid inspection on the premise of fasting blood drawing can inspect whether a certain individual has hyperlipidemia, but for some tested people only having postprandial dyslipidemia, the consumption, absorption and removal rate of the blood lipid is problematic, namely the fat tolerance is reduced, but the fasting dyslipidemia is not yet generated, the blood lipid inspection through the fasting state cannot be distinguished, the postprandial blood lipid level as an important risk factor of metabolic diseases is determined, and the blood lipid inspection has important significance for clinical early intervention;
postprandial hyperlipidemia is a pathological condition in which the total amount or part of lipid substances in human blood is higher than the normal range after a meal; the fat meal load test of a subject is researched, the serum triglyceride concentration in 8 hours before and after a meal is dynamically observed, and the multifactorial analysis shows that after the mixed influence of main coronary heart disease risk factors such as age, sex, basal metabolic rate (BMI) and smoking is eliminated, the postprandial blood lipid level is in obvious positive correlation with metabolic diseases;
in the process of checking the postprandial hyperlipidemia of a tested person, the total calorie taken by the tested person has no unified standard, so that the postprandial detection result also has no accurate reference value, although the research shows that the postprandial blood lipid level can predict the metabolic disease, the result is unstable because the calorie taken at home and abroad is not clear, a postprandial blood lipid level index is not determined for judging the occurrence risk of the metabolic disease, and the significance of observing the fat tolerance degree of the tested person after meal is lost;
the calorie of the high-fat meal used in the historical test of the inventor is as high as 1500kcal, the amount of the high-fat meal configured with 1500kcal is large, the oral taking of the patient is difficult, the taking time is long, the patient is intolerant due to large calorie, nausea is generated, even the situation of vomiting and diarrhea is caused, the absorption capacity of the patient is changed, a large number of patients participating in the test are quitted from the test midway, the test cannot continue to be propelled, 1500kca calorie is too large, the test performance of the two patients with fat and thin physique is greatly different, the test is unstable, the authenticity of the test is covered, and after the 1500kcal high-fat meal is used for a period of time, the patients cannot completely digest, the energy is excessive, and the blood fat level in the body cannot be recovered.
Disclosure of Invention
In order to solve the problems in the prior art, the invention provides a high-fat meal formula for a fat tolerance test.
In order to achieve the technical purpose and achieve the technical effect, the invention is realized by the following technical scheme:
a high fat meal formulation for a fat tolerance test, as shown in the following table:
each high-fat meal of the fat tolerance test is 200ml, and comprises 9.3g of saturated fatty acid, 18.6g of monounsaturated fatty acid, 18.6g of polyunsaturated fatty acid, 43.8g of protein, 26.2g of carbohydrate completely provided by glucose and 1.8g of sodium.
The invention has the beneficial effects that:
the invention provides a high fat meal formula for a fat tolerance test, which has the advantages that the probability of metabolic diseases of a tested person with reduced postprandial fat tolerance is higher than the probability of metabolic diseases of a tested person with normal postprandial fat tolerance by correlation research in the prior clinic, the total calorie is less than half of the total calorie of a historical test, the blood lipid reaction of the tested person after high fat load is observed, the problem that the static numerical value level of the tested person in the fasting state is only checked in the prior art and the high fat tolerance degree of the tested person after meal cannot be observed is solved, the high fat meal formula has certain clinical significance for screening early blood lipid metabolic disorder with partial fasting blood lipid normal, the possibility of the related diseases is prompted from early postprandial blood lipid data, the intake of the tested person is normalized by the formula proportioning of the high fat meal formula, and the accurate postprandial blood lipid data with reference significance is obtained, as reference data for predicting and evaluating the development of metabolic diseases of a tested person, under the judgment of professional medical field by using the reference data as intermediate data, intervenes the tested person as early as possible, delays or reduces the development of the tested person to the disease state, is popularized in clinic, solves the problem that the high fat tolerance condition of the tested person can not be observed, can judge the high fat tolerance of the patient in a non-fasting state in a unified standard, the high-fat meal formula for the fat tolerance test is more suitable for the gastrointestinal tolerance of Chinese people, so that the test patients can not nausea and vomiting caused by overhigh heat, the patient can not be because of intolerance midway release experiment, and the experiment is more stable, makes the patient absorb whole high fat meal, can not produce different test results because the physique is fat thin, and the experimental data is true, and patient's a period of time blood fat after the experiment resumes normal level.
Of course, it is not necessary for any product in which the invention is practiced to achieve all of the above-described advantages at the same time.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
The first group was administered 1500kcal of heat, 100 volunteers were recruited, 21 of them had gastrointestinal discomfort such as nausea and vomiting after eating high fat (15 of 21 had body weight less than 60kg), and 5 of them had been taken smoothly within 10 minutes and had diarrhea symptoms after eating, and these 26 subjects failed to complete subsequent blood sampling due to the above discomfort symptoms, and were withdrawn from the test in the middle, and finally 74 subjects completed all oral fat tolerance tests. The results are as follows
Table 1: 1500kcal test results
In the second group, 100 volunteers were subsequently recruited to take the high fat meal formula of the fat tolerance test of the present invention, all subjects took food within 10 minutes, 2 complained of mild nausea without dizziness, vomiting, etc., wherein 1 subject had diarrhea after 1 hour of the meal, exited the test, and the remaining 99 subjects had successfully completed the subsequent blood sampling.
Table 2: test results of high-fat meal formulation using the fat tolerance test of the present invention
And the third group subsequently recruits 100 volunteers to carry out 90% of the high fat meal formula of the fat tolerance test, all the subjects finish eating within 10 minutes, no complaints such as nausea and the like, no dizziness, vomit and the like, no diarrhea of the subjects, and 100 subjects successfully finish the subsequent blood sampling.
Table 3: test results of high-fat meal formula using 90% of fat tolerance test of the present invention
Through the table 1 of the first group of tests and the table 2 of the second group of tests, before the tests, patients quit the tests midway due to the fact that the patients do not react to 1500kcal high-fat meal, the body of the patients is not affected by the tests, the tests are affected, and only one patient feels uncomfortable due to the use of the high-fat meal formula of the fat tolerance test, so that the use experience of the patients participating in the tests is greatly improved, and the test promotion is promoted;
and the incidence of the postprandial hyperlipidemia is greater than that of the patients with normal postprandial hyperlipidemia in the incidence of various metabolic diseases, and the relevance of the postprandial hyperlipidemia and the metabolic diseases is proved, after the high fat meal formula of the fat tolerance test is used, the postprandial hyperlipidemia and the later incidence rate are improved compared with those of 1500kcal high fat meal, and the reaction is participated in patients who use 1500kcal high fat meal, some patients are misjudged as postprandial hyperlipidemia due to 1500kcal high-fat meal with excessive fat, the authenticity of the test is covered, through the third group of tests, by using 90% of the high-fat meal formula of the fat tolerance test of the invention, the incidence rate of metabolic diseases of normal patients after meals is increased, the incidence rate of metabolic diseases of hyperlipemia after meals is reduced, and the high-fat meal formula of the fat tolerance test of the invention with less reaction can cause part of the patients to be classified into normal groups as hyperlipemia after meals, so the high-fat meal formula of the fat tolerance test of the invention is the optimal scheme.
Example 2
The subsequent comparison of the change of triglyceride levels at different time points before the test and after oral administration of high fat meal shows that after 1500kcal of heat is given, the serum triglyceride level of a tested human group is obviously increased and still obviously higher than the fasting level after 10h of meal, and when the high fat meal formula of the fat tolerance test of the invention is given after the improvement, the change of the serum triglyceride is more smooth, and the serum triglyceride level is basically reduced to the fasting level after 8 h of meal, which indicates that 1500kcal of heat given once is overhigh, the blood fat load is overweight, the stability of the subsequent blood fat value is poor, and the subsequent data is more stable when the high fat meal formula of the fat tolerance test of the invention is given.
Example 3
All the subjects were grouped according to body weight, and it was found that the administration of 15000kcal of calories to the low-body weight group had an excessive load, resulting in a significant increase in postprandial blood lipids (table 5), and after the high-fat meal formulation of the fat tolerance test of the present invention (table 6), the low-body weight group subjects had good tolerance and stable postprandial response, suggesting that the high-fat meal formulation of the fat tolerance test of the present invention had a wider range of total caloric application of the high-fat meal
TABLE 4
TABLE 5
*：P＜0.05；**：P＜0.01。
The conclusion is drawn from the above table that the high-fat meal prepared by the invention normalizes the total calorie ingested by the tested person, and the metabolic disease is further predicted by screening the population with reduced lipid tolerance, so that the problem that the existing patients with hyperlipidemia can only be screened is solved, and the intervention on the tested person is carried out to delay the onset of disease.
In conclusion, the high-fat meal formula for the fat tolerance test provided by the invention regulates the intake of calories of the tested person through the formula proportion of calories, obtains accurate reference postprandial blood lipid data which are used as reference data for predicting and evaluating the development of metabolic diseases of the tested person, and intervenes the tested person as early as possible to prevent the tested person from developing to a disease state under the judgment of the professional medical field by using the reference data as intermediate data.
In the description herein, references to the description of "one embodiment," "an example," "a specific example" or the like are intended to mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
The preferred embodiments of the invention disclosed above are intended to be illustrative only. The preferred embodiments are not intended to be exhaustive or to limit the invention to the precise embodiments disclosed. Obviously, many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and the practical application, to thereby enable others skilled in the art to best utilize the invention. The invention is limited only by the claims and their full scope and equivalents.
Claims (2)
1. A high-fat meal formula for fat tolerance test is characterized in that: the composition consists of the following components: 9.3g of saturated fatty acid, 18.6g of monounsaturated fatty acid, 18.6g of polyunsaturated fatty acid, 43.8g of protein, 26.2g of carbohydrate and 1.8g of sodium;
the high fat meal formula of the fat tolerance test is 200ml in total.
2. The high fat meal formulation of fat tolerance test according to claim 1, characterized in that: the carbohydrate is composed entirely of glucose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111364115.5A CN114225052A (en) | 2021-11-17 | 2021-11-17 | High-fat meal formula for fat tolerance test |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111364115.5A CN114225052A (en) | 2021-11-17 | 2021-11-17 | High-fat meal formula for fat tolerance test |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114225052A true CN114225052A (en) | 2022-03-25 |
Family
ID=80749884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111364115.5A Pending CN114225052A (en) | 2021-11-17 | 2021-11-17 | High-fat meal formula for fat tolerance test |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114225052A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0189160A2 (en) * | 1985-01-22 | 1986-07-30 | Abbott Laboratories | High fat, low carbohydrate enteral nutritional formula |
| JPH09327299A (en) * | 1996-01-30 | 1997-12-22 | Nippon Ham Kk | Standard diet for measuring lipid in blood |
| CN103636792A (en) * | 2013-12-02 | 2014-03-19 | 光明乳业股份有限公司 | Nutrient milk powder |
| CN109430382A (en) * | 2018-11-12 | 2019-03-08 | 贝因美（杭州）食品研究院有限公司 | It is a kind of to have effects that adjust the formula food and preparation method thereof of blood glucose |
-
2021
- 2021-11-17 CN CN202111364115.5A patent/CN114225052A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0189160A2 (en) * | 1985-01-22 | 1986-07-30 | Abbott Laboratories | High fat, low carbohydrate enteral nutritional formula |
| JPH09327299A (en) * | 1996-01-30 | 1997-12-22 | Nippon Ham Kk | Standard diet for measuring lipid in blood |
| CN103636792A (en) * | 2013-12-02 | 2014-03-19 | 光明乳业股份有限公司 | Nutrient milk powder |
| CN109430382A (en) * | 2018-11-12 | 2019-03-08 | 贝因美（杭州）食品研究院有限公司 | It is a kind of to have effects that adjust the formula food and preparation method thereof of blood glucose |
Non-Patent Citations (1)
| Title |
|---|
| 侯晓宇: "口服脂肪耐量试验餐后血清甘油三酯水平与非酒精性脂肪肝的相关性研究", 硕士学位论文, 15 February 2021 (2021-02-15), pages 10 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abbasi et al. | The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial | |
| Dallongeville et al. | Short term response of circulating leptin to feeding and fasting in man: influence of circadian cycle | |
| Lai et al. | Effects of dietary fibers or probiotics on functional constipation symptoms and roles of gut microbiota: a double-blinded randomized placebo trial | |
| Hummel et al. | Postpartum outcomes in women with gestational diabetes and their offspring: POGO study design and first-year results | |
| Lima et al. | Effect of aerobic training and aerobic and resistance training on the inflammatory status of hypertensive older adults | |
| Zhou et al. | Benefits of different combinations of aerobic and resistance exercise for improving plasma glucose and lipid metabolism and sleep quality among elderly patients with metabolic syndrome: a randomized controlled trial | |
| Amelia et al. | The correlation between the level of HbA1c with total serum cholesterol of uncontrolled Type 2 diabetes mellitus patients in Binjai, Sumatera Utara | |
| Ramachandran et al. | Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes—a study in Indians | |
| Flanagan et al. | Identification of changes in sleep across pregnancy and the impact on cardiometabolic health and energy intake in women with obesity | |
| Berchtold et al. | Glucose tolerance, plasma insulin and lipids in relation to adipose tissue cellularity in men after myocardial infarction | |
| Oosthuizen et al. | Impact of urbanisation on serum lipid profiles-the THUSA survey | |
| Nikolaus et al. | Treatment of coronary heart disease with diet and exercise–problems of compliance | |
| CN114225052A (en) | High-fat meal formula for fat tolerance test | |
| Moayeri et al. | Overweight adolescents: a group at risk for metabolic syndrome (Tehran adolescent obesity study) | |
| Tian et al. | Sex differences in the association of weight-adjusted-waist index with sarcopenic obesity: A cross-sectional study of hemodialysis patients | |
| Hadaegh et al. | Seasonal variability of serum lipids in adults: Tehran Lipid and Glucose Study | |
| De Luis et al. | RS2289487 variation in PERILIPIN gene is a predictor of weight loss and protection against impaired glucose metabolism after a meal-replacement diet in postmenopausal obese females. | |
| ROSENBERG et al. | Screening for fat malabsorption | |
| JPWO2005018341A1 (en) | Food for testing lifestyle-related diseases | |
| CN110400640A (en) | A kind of research method of low carbohydrate diet to non-alcoholic fatty liver disease | |
| Hong et al. | Associations of Plasma and Fecal Metabolites with Body Mass Index and Body Fat Distribution in Children | |
| Sane et al. | One‐year response to evening insulin therapy in non‐insulin‐dependent diabetes | |
| Kelly et al. | Gastrointestinal cell injury and perceived symptoms after running the Boston Marathon | |
| Hsieh et al. | Metabolic characteristics in individuals with impaired glucose homeostasis | |
| Lamsal et al. | Prevalence of Diabetes and Dyslipidemia in Hypertensive Young Adults in a Tertiary Care Centre in Nepal, a Cross Sectional Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |